Simplify Logo

Full-Time

Director – Medical Affairs Training

Updated on 9/6/2024

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharmaceuticals for eye and infectious diseases

Hardware
Biotechnology

Compensation Overview

$191.2k - $267.8kAnnually

+ Bonus + Stock Equity

Senior, Expert

United States

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Advanced degree (OD, MD, PhD., or PharmD) with knowledge of eye care preferred.
  • Minimum of 10 years pharmaceutical experience with at least 5 years in medical affairs.
  • Strong interpersonal and communications skills, both written and verbal.
  • Exceptional project management and training event planning skills.
  • Critical thinking, leadership skills, assertiveness, excellent negotiation skills evidenced by past performance on medical affairs teams.
  • Ability to thrive in a fast-paced, entrepreneurial environment.
  • Must possess a thorough understanding of the FDA, OIG, HIPAA, PhRMA, and other guidelines relevant to the pharmaceutical industry and to ensure compliance with these external and Tarsus compliance guidelines and standard operating procedures.
  • A high attention to detail and ability to lead and prioritize assigned projects.
  • Experience with Veeva vault and medical legal review process.
Responsibilities
  • Develop annual strategic training plan aligned with medical objectives and insights.
  • Identify field medical needs and create impactful innovative customer-facing tools for SMAs.
  • Manage projects through the MLR (medical legal regulatory) review process.
  • Plan, manage, and execute live training sessions, including logistics and coordination.
  • Lead onboarding for new Senior Medical Ambassadors (SMAs) and provide feedback.
  • Ensure compliance with PhRMA guidelines and Tarsus policies.
  • Plan and manage clinic preceptorships and any live training at major medical meetings.
  • Lead planning for major medical congresses and manage all related activities and engagements.
  • Accompany SMAs on field visits to determine training needs and evaluate tool use
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for other conditions, including Lyme Disease Prevention and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. The goal of Tarsus Pharmaceuticals is to provide effective medical treatments that improve patient outcomes in areas where there are currently few options.

Company Stage

IPO

Total Funding

$610.6M

Headquarters

Irvine, California

Founded

2017

Growth & Insights
Headcount

6 month growth

5%

1 year growth

12%

2 year growth

192%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $200 million in non-dilutive financing from Pharmakon Advisors strengthens Tarsus's financial position, enabling further R&D and market expansion.
  • Positive Phase 2a trial results for TP-05 for Lyme Disease prevention indicate promising future product offerings and potential market growth.
  • Recognition through awards like the Zero to Launch Award highlights Tarsus's innovative approach and successful commercialization strategies.

What critics are saying

  • The biopharmaceutical market is highly competitive and capital-intensive, requiring continuous innovation and substantial investment to maintain a competitive edge.
  • Dependence on the success of a limited number of products, such as XDEMVY, makes the company vulnerable to market fluctuations and regulatory changes.

What makes Tarsus Pharamceuticals unique

  • Tarsus Pharmaceuticals focuses on high unmet medical needs in eye care and infectious diseases, setting it apart from competitors with broader but less specialized portfolios.
  • Their flagship product, XDEMVY, is FDA-approved for treating Demodex Blepharitis, a niche condition with limited treatment options, giving them a unique market position.
  • The company's commitment to ethical operations and robust compliance programs ensures trust and reliability among healthcare providers and patients.